Abstract
Background:
Schizophrenia is associated with very high rates of tobacco smoking. The latter may be related to an attempt to “self-medicate” symptoms and/or to alterations in function of high affinity nicotinic acetylcholine receptors (β2*-nAChRs).
Methods:
Smoking and nonsmoking subjects with schizophrenia (n=31) and age-, smoking- and sex-matched comparison subjects (n=31) participated in one [123I]5-IA-85380 single photon emission computed tomography (SPECT) scan to quantify β2*-nAChR availability. Psychiatric, cognitive, nicotine craving and mood assessments were obtained during active smoking as well as smoking abstinence.
Results:
There were no differences in smoking characteristics between smokers with and without schizophrenia. Subjects with schizophrenia had lower β2*-nAChR availability relative to comparison group, and nonsmokers had lower β2*-nAChR availability relative to smokers. However, there was no smoking by diagnosis interaction. Relative to nonsmokers with schizophrenia, smokers with schizophrenia had higher β2*-nAChR availability in limited brain regions. In smokers with schizophrenia, higher β2*-nAChR availability was associated with lower negative symptoms of schizophrenia and better performance on tests of executive control. Chronic exposure to antipsychotic drugs was not associated with changes in β2*-nAChR availability in schizophrenia.
Conclusions:
Although subjects with schizophrenia have lower β2*-nAChR availability as compared to comparison group, smokers with schizophrenia appear to upregulate in the cortical regions. Lower receptor availability in smokers with schizophrenia in the cortical regions is associated with a greater number of negative symptoms and worse performance on tests of executive function; suggesting smoking subjects with schizophrenia who upregulate to a lesser degree may be at risk for poorer outcomes.
Keywords: nicotinic acetylcholine receptors, psychosis, tobacco smoking, negative symptoms, executive control, SPECT
Introduction
Schizophrenia is associated with very high rates of tobacco addiction (80%) relative to the general population (20%) (1, 2). Compared to typical smokers from the general population, individuals with schizophrenia are reported to extract higher amounts of nicotine per cigarette and higher rates of smoking-related cardiovascular disease, pulmonary disease and associated mortality (3, 4). The high rate of tobacco smoking may reflect an attempt to “self-medicate” the negative symptoms, cognitive dysfunction, and antipsychotic-related side-effects associated with schizophrenia (1, 5-9). Therefore, understanding the basis for high rates smoking in this population, a modifiable risk factor, might lead to increased life expectancy and quality of life, and may also provide the basis for developing drugs to target the symptoms of schizophrenia.
Nicotine, the primary addictive and reinforcing constituent in cigarettes, has high affinity for the beta2-subunit containing nicotinic acetylcholine receptors (β2*-nAChRs). Evidence from postmortem (10), preclinical (11), and clinical (12, 13) studies demonstrates that chronic administration of nicotine and tobacco smoking increases the number of β2*-nAChRs in most brain regions (12, 14), a process that is commonly referred to as “upregulation”. However, results from a post- mortem study suggests that smokers with schizophrenia fail to upregulate β2*-nAChRs to the same extent as comparison smokers. This post mortem study that controlled for smoking status showed that while nonsmokers with and without schizophrenia have similar binding of [3H]-nicotine (symbolizing similar availability of β2*-nAChRs), smokers with schizophrenia have lower [3H]-nicotine binding than smokers without schizophrenia. Taken together these findings suggested that smokers with schizophrenia do not upregulate nAChRs to the same extent as smokers without schizophrenia (15). We confirmed in vivo the postmortem findings of Breese et al. that smokers with schizophrenia had lower β2*-nAChR availability relative to smokers without schizophrenia (16). Furthermore, we showed that β2*-nAChR availability in individuals with schizophrenia correlated with negative symptoms (16). However, because our initial study did not include nonsmokers with schizophrenia, we were unable to determine whether smoker with schizophrenia do not upregulate nAChRs.
The overarching goal of the current study was to determine the role of β2*-nAChRs in schizophrenia-associated symptomatology. β2*-nAChRs have been previously quantified with high affinity radioligand [123I]-5 -iodo-3-[2(S)-2-azetidinylmethoxy]pyridine ([123I]5-IA) (17) and SPECT (18). in a range of clinical samples including individuals with nicotine addiction (19, 20), alcohol use disorders (21), major depressive disorder (22), bipolar disorder (23), and schizophrenia (16)) [123I]5-IA has slow dissociation from the receptor–ligand complex, a good specific to nonspecific binding ratio, and high selectivity for β2 *-nAChRs (18, 24). We hypothesized that although there would be overall lower β2*-nAChR availability in individuals with vs. without schizophrenia, we would observe higher β2*-nAChR availability in smokers vs. nonsmokers with schizophrenia in the cortex, hippocampus, and striatum based on previous postmortem findings (15). Second, we hypothesized that the lower β2*-nAChR availability, the more severe the schizophrenia-associated symptoms. Third, we hypothesized that the lower β2*-nAChR availability, the more severe the cognitive deficits. Finally, an exploratory aim was to determine the influence of chronic antipsychotic treatment on β2*-nAChR availability in schizophrenia.
Methods
Approvals
This study was approved by the Yale University and VA Connecticut Healthcare System Institutional Review Boards. All participating subjects signed informed consent after the study was explained to them in detail (see supplement).
Subjects
Thirty one subjects with schizophrenia (2 women smokers; 22 smokers, 4 of whom were unmedicated; 9 nonsmokers 2 of whom were unmedicated) and 31 age- and sex-matched comparison subjects (2 women smokers; 22 smokers, 9 nonsmokers) completed the study and were included in the analyses. Data from the previous sample of smoking subjects with and without schizophrenia (16) are included here as part of this study. Thus, 11 medicated smokers with schizophrenia and 11 smoking controls are included from the previously sample in order to test the hypothesis of higher β2*-nAChR availability in smokers.
Subjects completed a comprehensive screening process (see supplement. A psychiatric, medical and neurological evaluation was completed by a research physician. A structured clinical interview for DSM-IV (SCID) to verify the primary diagnoses of schizophrenia (or lack thereof for comparison group) was conducted. In addition, for the schizophrenia group, information collected by clinical evaluation, SCID data, review of the medical record and contact with the patient’s clinician was used to confirm the diagnosis and to exclude subjects with any other disorders other than nicotine dependence. Comparison subjects were excluded for lifetime exposure to psychiatric medication, except for smoking cessation attempts (and none in the past year). Nicotine dependence was evaluated with the Fagerström Test for Nicotine Dependence (20). Smoking status at screening was verified by a plasma cotinine level > 150 ng/ml, urine cotinine level > 100 ng/ml, and carbon monoxide (CO) level > 11 ppm at baseline. Nonsmoking status was ascertained by self-report, plasma cotinine level < 15 ng/ml, breath CO levels < 8 ppm at baseline and scan day, and urine cotinine levels < 50 ng/ml. All nonsmokers were never smokers. Lifetime history of and current substance use disorders was ascertained by psychiatric interview, chart review (only in schizophrenia patients), SCID, 30-day Timeline Follow Back and urine toxicology.
In the schizophrenia group only clinically stable subjects were included. Those schizophrenia taking antipsychotic medications were required to be taking a stable dose for the past 12 weeks. Benzodiazepines were permitted on an as-needed basis for subjects with schizophrenia, but not within 12 hours of testing. Subjects taking tricyclic antidepressants, anticholinergics, or selective serotonin reuptake inhibitors were excluded because there is some evidence that these drugs interfere with [123I]5-IA binding.
Smoking Cessation
Approximately 1 week of abstinence from tobacco smoking is required to clear nicotine from the brain so that it will not interfere with [123I]5-IA binding (21). To help the subjects abstain from smoking for at least 5 days before the SPECT scan day, they were given brief behavioral counseling based on clinical practice guidelines and contingency management (16). Eligible smokers with schizophrenia were hospitalized on a smoke-free unit and were not allowed to use drugs for smoking cessation, since these could alter [123I]5-IA binding. Abstinence from smoking and other nicotine products was confirmed by daily monitoring of breath carbon monoxide (CO) and dipstick measurement of urinary cotinine. The CO and urine cut off on scan day were < 8ppm and < 50 ng/ml, respectively. Nicotine craving and withdrawal were evaluated using the Tiffany Urge to Smoke Questionnaire (22) and the Minnesota Nicotine Withdrawal Scale (23), respectively, at intake, during smoking cessation, and on the SPECT scan day. Two factors of Tiffany Smoking Urges Questionnaire were employed: desire (positive symptoms associated with wanting a cigarette; e.g., “I have an urge to smoke”) and relief (withdrawal relief expected if cigarette is smoked; e.g., “Nothing would be better than smoking a cigarette right now”).
Behavioral Testing
Positive, negative, and general symptoms of schizophrenia were measured by the Positive and Negative Syndrome Scale (PANSS) (24) and the Scale for the Assessment of Negative Symptoms (SANS) (25). Depressive symptoms were assessed by the Montgomery-Åsberg Depression Scale (MADRS) (26), and involuntary movements were evaluated with the Abnormal Involuntary Movement Scale (AIMS) (27).
Cognitive testing
Executive control was assessed using the Stroop Color-Word Test (25) and Wechsler Digit Symbol Test (this test assesses several functions including executive control and processing speed; (26)). Subjects participated in cognitive testing: 1) at baseline to familiarize them with cognitive testing (baseline 1), 2) a second baseline to obtain measures of cognitive performance without the factor of novelty (baseline 2), 3) one day after smoking cessation, and 4) on SPECT scan day (after 1 week of smoking abstinence). Nonsmoking subjects were administered cognitive testing at the same time points.
Magnetic Resonance Imaging
Each subject participated in one magnetic resonance imaging (MRI) scan prior to SPECT scanning on a Signa 1.5T system (General Electric Co, Milwaukee, Wis) as described previously (27).
SPECT Imaging
[123I]5IA was synthesized (28) and administered through a venous catheter using a bolus-plus-constant-infusion paradigm with a ratio of 7.0 ± 0.03 h for the smokers with schizophrenia, 7.0 ± 0.03 h for the nonsmokers with schizophrenia, 7.0 ± 0.02 h for the comparison smokers, and 7.0 ± 0.04 h for the comparison nonsmokers. SPECT emissions (3 × 30-min static emissions) and transmission scans were collected 6-8 hrs after initiation of [123I]5IA administration as described previously (13, 16). Total injected dose (accounting for decay) of 345.0 ± 31.3 MBq for the smokers with schizophrenia, 355.7 ± 33.9 MBq nonsmokers with schizophrenia, 332.2 ± 41.9 MBq comparison smokers, and 352.2 ± 49.6 MBq for the comparison nonsmokers. Blood was drawn prior to injection and in the middle of the emission scans for analysis of plasma total parent and free fraction of parent tracer in plasma (fP, free fraction). The chemical fate of [123I]5-IA post injection was assessed in plasma as previously described (29).
SPECT Image Analysis
SPECT emission images were analyzed as described previously (16). A co-registered MR image was used to guide the placement of standard 2-dimensional region of interest (ROI) templates using MEDx software (Medical Numerics, Inc.). A 3D volume of interest was generated for each region and transferred to the co-registered SPECT image to determine regional radioactive densities. The chosen regions contain β2*-nAChRs and have been examined in the postmortem study and included the frontal and parietal cortices, thalamus, striatum (an average of caudate and putamen), and hippocampus. Regional [123I]5IA uptake was determined by VT/fp where VT is volume of distribution and fp is free plasma fraction (calculated as regional activity divided by free plasma parent between 6 and 8 hours of infusion), was used to correct for possible differences in radiotracer metabolism or plasma protein binding between groups and subjects (30).
Statistical analyses
Statistical analysis was performed using IBM SPSS v19.0 (Armonk, New York). Statistical significance was set at p<0.05, two-tailed. Two (diagnosis) by two (smoking status) multivariate analysis of variance was used to measure differences in receptor availability between experimental groups. Differences between cognitive and clinical outcomes at different time points were evaluated within groups using two-tailed, paired t-tests. Spearman correlation coefficient was employed to measure associations between receptor availability and clinical and cognitive variables.
Results
Demographic characteristics for all groups are listed in Table 1. There were no significant differences in age between any of the groups (p>0.2). There were no significant differences in any smoking characteristics between smokers with and without schizophrenia for the number of cigarettes smoked daily, nicotine dependence, relief, desire or withdrawal at baseline or on scan day (p>0.21). There were no significant differences in CO or urine cotinine levels on the day of the scan between smokers with and without schizophrenia (p>0.36).
Table 1.
Subject characteristics.
SczS (n=22) | SczNS (n=9) | CS (n=22) | CNS (n=9) | All Scz (n=31) | All Control (n=31) |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
Age | 42.1 | 11.1 | 38.5 | 14.8 | 39.7 | 10.9 | 35.1 | 12. 1 |
41.1 | 12.0 | 38.3 | 11.3 |
Yrs smoking | 25.6 | 12.7 | 19.3 | 11.0 | ||||||||
Cig/day | 20.7 | 7.0 | 18.9 | 8.1 | ||||||||
Age of diagnosis | 23.9 | 7.5 | 25.9 | 9.4 | 24.4 | 7.9 | ||||||
Yrs diagnosed | 17.3 | 10.4 | 10.6 | 10.4 | 15.6 | 10.6 | ||||||
Baseline assessments | ||||||||||||
FTND | 5.7 | 1.9 | 4.9 | 2.8 | ||||||||
MSWQ | 7.7 | 5.9 | 4.9 | 7.1 | ||||||||
Tiffany QSU Desire | 34.5 | 13.8 | 33.2 | 14.3 | ||||||||
Tiffany QSU Relief | 32.7 | 11.0 | 26.3 | 11.5 | ||||||||
PANSS positive | 19.2 | 4.3 | 18.3 | 2.7 | 18.9 | 3.8 | ||||||
PANSS negative | 35.0 | 5.7 | 36.3 | 7.5 | 20.5 | 5.3 | ||||||
PANSS total | 73.0 | 9.6 | 79.2 | 11.7 | 74.8 | 10.4 | ||||||
SANS | 30.4 | 14.8 | 44.1 | 21.5 | 34.4 | 17.8 | ||||||
Scan day assessments | ||||||||||||
MSWQ | 4.4 | 4.5 | 2.7 | 4.1 | ||||||||
Tiffany QSU Desire | 26.9 | 11.2 | 19.0 | 10.4 | ||||||||
Tiffany QSU Relief | 26.8 | 10.3 | 17.9 | 8.7 | ||||||||
PANSS positive | 19.6 | 4.0 | 17.9 | 2.3 | 19.2 | 3.7 | ||||||
PANSS negative | 18.5 | 4.7 | 23.3 | 3.3 | 19.7 | 4.9 | ||||||
PANSS total | 74.7 | 9.3 | 76.4 | 10.8 | 75.2 | 9.6 | ||||||
SANS | 32.3 | 16.1 | 48.5 | 18.0 | 36.6 | 17.9 |
SczS – smokers with schizophrenia; SczNS – nonsmoker with schizophrenia; CS – control smoker; CNS – control nonsmoker.
VT/fp
There were no significant differences in fp between subjects with and without schizophrenia (scz fp 0.35 ± 0.05; control fp 0.36 ± 0.05; p=0.47). There was a significant effect of smoking status (Hotelling’s trace F=3.2, p=0.01) and diagnosis of schizophrenia (Hotelling’s trace, F=7.4, p=0.00) but no significant interaction between smoking and schizophrenia (p=0.67) on β2*-nAChR availability. Overall, smokers had higher VT/fp as compared to nonsmokers in all the regions assessed: frontal F(1,59)=5.4, p=0.02) and parietal (F(1,59)=4.4, p=0.04) cortices, thalamus (F(1,59)=8.3, p=0.006), striatum (F(1,59)=18.0, p=0.000) and hippocampus (F(1,59)=5.9, p=0.02)). Subjects with schizophrenia had significantly lower (13%) VT/fp as compared to comparison group in the frontal (F(1,59)=5.4, p=0.02) and parietal (F(1,59)=4.4, p=.04) cortices, but not in the subcortical regions where the differences were 2-5% (p>.42) (Figure 1, Table 2).
Fig. 1.
Scatter plot of VT/fp in the parietal and frontal cortices, thalamus, striatum and hippocampus in subjects with schizophrenia who are smokers (closed circles) and nonsmokers (open circles), comparison subjects who are smokers (closed diamonds) and nonsmokers (open diamonds), all subjects with schizophrenia (closed triangles), and all comparison (open triangles). We observed a main effect of smoking (Hotelling’s trace F=3.2, p=.01) and diagnosis of schizophrenia (Hotelling’s trace, F=7.4, p=.00) but no significant interaction of smoking by schizophrenia (p=.67) on VT/fp. Overall, smoking subjects had greater receptor availability as compared to nonsmokers, and subjects with schizophrenia had lower receptor availability as compared to those without schizophrenia.
To explore whether the difference in VT/fp between smokers and nonsmokers was the same between groups, a secondary analysis (MANOVA) was conducted dividing the groups into subjects with and without schizophrenia. This revealed a statistically significant effect of smoking in the comparison group (Hotelling’s Trace F=4.2, p=0.006), and with significant differences in all the regions assessed (frontal F(1,30)=7.8, p=0.009) and parietal (F(1,30)=10.3, p=0.003) cortices, thalamus F(1,30)=5.4, p=0.027), striatum (F(1,30)=11.3, p=0.002) and hippocampus (F(1,30)=4.4, p=0.044)). In the schizophrenia group, there was a statistically significant effect of smoking (Hotelling’s Trace F=4.2, p=0.007), and the difference was significant in the frontal F(1,30)=10.4, p=0.003) and parietal (F(1,30)=8.2, p=0.008) cortices, and striatum (F(1,30)=7.1, p=0.012), but not in the thalamus (F(1,30)=3.0, p=0.092) or hippocampus (F(1,30)=2.0, p=0.165).
Symptoms Measures and VT/fp
There were no differences in the positive symptoms (PANSS), depression (MADRS) or dyskinesia (AIMS) scores between smokers and nonsmokers with schizophrenia at baseline or on scan day (after smokers abstained from smoking) (p>0.25) (Table 1). There were no significant changes in depressive, positive or negative symptoms in smokers on scan day (smoking abstinence) as compared to baseline. At baseline and on scan day, compared to nonsmokers with schizophrenia, smokers with schizophrenia had lower negative symptoms scores measured by the PANSS negative symptoms subscale scores (baseline PANSS F(1,27)=5.1, p=0.03; scan day PANSS (F(1,26)=6.4, p=0.018) and SANS (baseline SANS F(1,27)=3.1, p=0.09).
A negative correlation between negative symptoms measured by both the PANSS negative symptom subscale and SANS and VT/fp was observed in the frontal and parietal cortices and striatum in the overall sample of subjects with schizophrenia at baseline and on scan day (Figure 2). This effect appears to be driven by smokers because a subsequent subgroup (smokers vs. nonsmokers) analysis revealed a significant negative correlation between negative symptoms and VT/fp only in smokers with schizophrenia (Figure 2). No significant correlations were observed between MADRS depression scores and VT/fp.
Fig. 2.
Negative association between VT/fp and negative symptoms were observed in the total sample of subjects with schizophrenia on the PANSS and SANS in the parietal (shown here) and frontal cortices and striatum. Total sample: Frontal (PANSS r=−0.52, n=31, p=0.003; SANSS r=−0.40, n=31, p=0.03) and parietal (PANSS r=−0.55, n=31, p=0.002; SANSS r=−0.53, n=31, p=0.003) cortices and striatum (PANSS r=−0.40, n=31, p=0.03; SANSS r=−0.38, n=31, p=0.04). However, when we stratified the sample by smoking, this observation persisted in the smoking sample only. Frontal: PANSS r=−0.45, n=22, p=0.04 and parietal (PANSS r=−0.53, n=22, p=0.01 SANSS r=−0.50, n=22, p=0.02).
Executive control and VT/fp
There were no differences in performance on cognitive measures between smokers and nonsmokers with schizophrenia at any time points. In smokers with schizophrenia, there was a positive correlation between performance on the Stroop Color-Word test (Interference score) and VT/fp in the frontal (r=0.59, n=17, p=0.012) and parietal cortices (r=0.59, n=17, p=0.013) (Figure 3), and between Digit Symbol score and VT/fp in the frontal (r=0.48, n=21, p=0.027) and parietal cortices (r=0.44, n=21, p=0.047).
Fig. 3.
Significant positive associations were observed between VT/fp and performance on tests of executive control in the group of smokers with schizophrenia (Stroop Color-Word test shown here): in the frontal (r=.59, n=17, p=.012) and parietal cortices(r=.59, n=17, p=.013).
Smoking characteristics and VT/fp
There were no significant associations between receptor availability and any smoking characteristics in smokers with schizophrenia (all p>0.17), including nicotine dependence, years and numbers of cigarettes smoked. Further, there were no significant associations between cigarette craving and VT/fp on scan day (p>0.11).
Antipsychotic Medication and VT/fp
Exploratory analyses (22 smokers, 4 of whom where unmedicated; 9 nonsmokers 2 of whom were unmedicated) were conducted to examine whether treatment with antipsychotic medication was related to VT/fp in subjects with schizophrenia. Since there was a significant age difference between medicated and unmedicated subjects with schizophrenia (F(1,28)=4.7, p=0.039), age was entered as a covariate. We did not observe statistically significant effect of antipsychotic medication status (p=0.235).
Discussion
This study examined the effect of smoking and schizophrenia on an in vivo measure of VT/fp. First, we detected lower regional VT/fp in schizophrenia regardless of smoking status. Second, we observed that smokers with schizophrenia have significantly higher VT/fp than nonsmokers in several brain regions. Third, we extend the findings of a negative correlation between VT/fp and negative symptoms in smokers with schizophrenia in a larger sample. Fourth, performance on tests of executive control is positively correlated with VT/fp. Fifth, chronic treatment with antipsychotic medications does not appear to influence VT/fp.
Effect of Diagnosis on VT/fp
Individuals with schizophrenia have significantly lower VT/fp in cortical regions as compared to those without schizophrenia; however, smokers with schizophrenia show region-specific upregulation of these receptors. We had previously reported lower VT/fp in a small sample (n=11) of smoking subjects with schizophrenia as compared to comparison smokers (16). Here, we extend these findings to a larger sample of smokers with schizophrenia as well as nonsmokers with schizophrenia and show lower VT/fp across smoking groups. The lower VT/fp observed in schizophrenia might contribute to the increased smoking observed in this population. Higher VT/fp in smokers is believed to partially represent greater numbers of desensitized and inactivated nAChRs (31, 32), therefore, the lower VT/fp in schizophrenia may reflect altered receptor functionality, since maintained nAChR desensitization may be important for relieving nicotine withdrawal in human smokers (33).
Effect of Smoking Status on VT/fp
In order to determine whether smokers with schizophrenia upregulate their β2*-nAChRs, and to determine the role this system plays in smoking in schizophrenia, nonsmokers with the illness were included in this study. An effect of schizophrenia and smoking status was observed on VT/fp but not a diagnosis by smoking interaction: as a group, individuals with schizophrenia have lower VT/fp as compared to those without schizophrenia and all smokers regardless of having a diagnosis of schizophrenia have higher VT/fp. While the lack of diagnosis by smoking interaction suggests that the degree of upregulation is not significantly different between the schizophrenia and control groups, in the patient group, the degree of upregulation was significant only in the frontal and parietal cortices, and striatum, but not thalamus or hippocampus. These data suggest that smokers with schizophrenia show a different pattern of nAChR upregulation than the general population.
Relationship between Schizophrenia Symptoms and VT/fp
There was a specific and robust inverse relationship between VT/fp and negative symptoms in smokers with schizophrenia (16). Regardless of the measure of negative symptoms (SANS or PANSS) used, patients with lower VT/fp reported greater number negative symptoms. This finding is consistent with a recent report of a negative correlation between negative symptoms and [3H]-nicotine binding to nAChRs in the lymphoblast model ((34). It is tempting to speculate whether schizophrenia patients smoke to alleviate negative symptoms. Some studies report that schizophrenic patients who smoked heavily had the lowest number of negative symptoms (35). However it should be noted that studies on the association between symptom domains and smoking have yielded conflicting results, with studies suggesting a positive correlation between smoking variables and negative symptoms, a negative correlation between smoking variables and negative symptoms, or no relationship between smoking variables and symptoms ((35-51). Smoking high nicotine cigarettes decreases negative symptoms to a greater extent than smoking denicotinized cigarettes (52). Similarly, some but not other clinical trials have demonstrated beneficial effects of nAChR agonists on negative symptoms (53-56). Interestingly, the nAChR agonist TC-5619 had stronger effects on reducing negative symptoms in smokers with schizophrenia (56) a finding that is consistent with our observation that the relationship between β2*-nAChR availability and negative symptoms is present only in smokers. While admittedly speculative, one mechanism through which nicotine could reduce negative symptoms may be related to the ability of nicotine to increase burst-firing of dopaminergic neurons and increase dopamine release (57-59), thereby correcting the cortical hypodopaminergia that may mediate negative symptoms (60). Thus, treatments based on a β2*-nAChR mechanism may be useful for treating negative symptoms in smokers with schizophrenia, and would likely contribute to improved smoking cessation treatments in these individuals.
Relationship between Executive Function and VT/fp
There was a positive association between VT/fp in the frontal and parietal cortices and performance on tests related to executive control (Stroop Color-Word test and Digit Symbol subtest) in smokers with schizophrenia. Thus, smokers with schizophrenia who have higher VT/fp may have better executive control. The frontal and parietal cortices both regulate executive functioning (61), and these findings support the idea that a balance of cholinergic neurotransmission is required for normal cognition. Regional VT/fp may therefore play a critical role in these brain areas in those with and without psychiatric illness; however, despite evidence implicating the cholinergic system in the neurobiology of cognitive dysfunction of schizophrenia (62, 63), the effects of drugs targeting nAChRs for cognitive deficits associated with schizophrenia have been mixed. For example, nicotine preferentially enhanced attentional processing in individuals with schizophrenia and their first-degree relatives as compared to typical individuals (8, 64) and tobacco smoking cessation impaired visuospatial working memory in smokers with schizophrenia but not in smokers without schizophrenia (8); however, augmentation with the selective α4β2-nAChR agonist AZD3480 failed to improve performance on the MATRICS and Integneuro battery in schizophrenia patients (n>400) who were receiving typical antipsychotics (65). The effects of varenicline, an α4β2-nAChR partial agonist and a low affinity α7-nAChR agonist (66), are also mixed. Some studies have demonstrated improvements in executive control in smokers with schizophrenia (66, 67) and another found varenicline improved verbal learning and memory but not attentional or visuospatial indices (52). The varied outcome measures used makes a collective interpretation of these studies challenging, especially since these studies are further confounded by subjects’ smoking status. It is likely that in smokers, high affinity nAChRs are fully occupied by nicotine derived from smoking and additional nAChR agonists may, therefore, not produce any effects. In trials testing nAChR agonists in acutely abstinent smokers, it is difficult to tease out the procognitive effects of nAChR agonists from the effects of reversing nicotine withdrawal. Investigations are currently underway which may provide further evidence for beneficial effects of varenicline and other drugs that act at β2*-nAChR for cognitive dysfunction in schizophrenia.
Relationship between Antipsychotic Exposure and β2*-nAChR availability
Consistent with preclinical data (68), in this study chronic exposure to dopamine D2 receptor antagonist antipsychotic medications was not significantly related to VT/fp. This would suggest that group differences in VT/fp cannot be explained by an effect of chronic exposure to antipsychotic medications. The limited number of unmedicated subjects studied limits evaluation of medication by smoking interaction, but should be evaluated in future studies.
Effect of Smoking Cessation on Symptoms
Consistent with our previous study (16), in this extended sample of smokers with schizophrenia, smoking cessation and short-term abstinence had no significant effects on positive symptoms, negative symptoms or depression ratings. These data do not support the “self-medication” hypothesis according to which individuals with schizophrenia smoke to alleviate positive and negative symptoms and depression. Nevertheless, in this larger sample, most smokers with schizophrenia resumed smoking immediately after completing the SPECT scan, which supports the facts that it is so much more difficult for them to quit smoking, and thus much more effective treatments and more behavioral support is needed in this population.
Limitations and future directions:
There were some limitations to this study. First, the smoking sample included subjects from previously published study (16); however, inclusion of that sample was important in order to evaluate whether smokers with schizophrenia show β2*-nAChR upregulation. Second, the sample was composed primarily of male subjects. Since we previously showed sex-specific differences in β2*-nAChR upregulation in non-psychiatric subjects (69), it is possible that a larger cohort of female smokers may reveal different results. Third, given that sample of unmedicated individuals with schizophrenia was limited and the groups were less than ideally matched, the interactions between VT/fp and antipsychotic treatment should be interpreted cautiously. Fourth, whether the lower VT/fp is present at the onset of the illness or is a consequence of the illness and/or treatment cannot be established without studying unmedicated prodromal patients. Showing abnormalities in VT/fp in prodromal patients might provide one explanation for the higher rates of smoking in individuals who go on to develop schizophrenia. Fifth, illness duration was not well matched between nonsmoking and smoking subjects with schizophrenia and could influence the observed differences in VT/fp. Sixth, region volumes were not checked, and therefore we cannot rule out the possibility that regional volume differences with resultant partial volume effects contributed to the measurements. Finally, cognitive tasks that preferentially load prefrontal cortical function will be used in future studies to link β2*-nAChR availability, prefrontal cortical function and negative symptoms.
To conclude, we extended our previous findings to show that although VT/fp is lower in individuals with schizophrenia, smokers with schizophrenia have higher VT/fp compared to nonsmokers, suggesting an upregulation of β2*-nAChRs. Lower VT/fp in subjects with schizophrenic might contribute to the vulnerability to smoking in this population. Furthermore, this system may play a role in negative symptoms and executive dysfunction: two important symptom domains in schizophrenia for which existing treatments have limited efficacy. These data support targeted development of nAChR agonists to treat negative symptoms and executive dysfunction in smokers with schizophrenia.
Supplementary Material
Table 2.
VT/fP by group
Region | SczS (n=22) |
SczNS
(n=9) |
CS (n=22) | CNS (n=9) |
All Scz
(n=31) |
All Control
(n=31) |
% dif
Scz vs Control |
P | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |||
Parietal | 47.1 | 14.0 | 33.4 | 5.0 | 54.2 | 12.9 | 40.0 | 7.9 | 43.1 | 13.5 | 49.8 | 13.2 | 13.4 | .04 |
Frontal | 51.1 | 14.4 | 35.2 | 3.8 | 58.2 | 13.7 | 44.7 | 11.3 | 46.5 | 14.3 | 53.9 | 14.4 | 13.8 | .02 |
Thalamus | 120.1 | 30.7 | 101.5 | 12.1 | 128.9 | 28.5 | 105.3 | 29.8 | 114.7 | 27.8 | 120.9 | 30.9 | 5.1 | >.10 |
Striatum | 75.1 | 19.5 | 56.8 | 8.9 | 78.0 | 16.7 | 58.9 | 13.6 | 69.8 | 19.0 | 71.7 | 18.2 | 2.7 | >.10 |
Hippocampus | 78.5 | 24.9 | 65.8 | 13.9 | 74.7 | 16.6 | 62.7 | 20.5 | 74.8 | 22.8 | 70.3 | 18.8 | −6.4 | >.10 |
SczS – smokers with schizophrenia; SczNS – nonsmoker with schizophrenia; CS – control smoker; CNS – control nonsmoker
Acknowledgements
This research was funded by R01 DA -022495 (D.C.D.), NARSAD (I.E.) and R01DA015577 (K.P.C.). Salary support was provided by MH077681 and DA14241 (M.R.P.), K01MH092681 (I.E.) and K02DA031750 (K.P.C.).
The authors wish to acknowledge support from the Department of Veterans Affairs. The authors also thank staff of the Clinical Neuroscience Research Unit of the Connecticut Mental Health Center in caring for patients while they were hospitalized to achieve abstinence from smoking.
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflicts of interest: All authors report no biomedical financial interests or potential conflicts of interest for this study. Deepak Cyril D’Souza has in the past three years or currently received research grant support administered through Yale University School of Medicine from Astra Zeneca, Abbott Laboratories, Eli Lilly Inc., Forest Laboratories, Organon, Pfizer Inc., and Sanofi; he is a consultant for Bristol Myers Squibb and Johnson & Johnson. Marina Picciotto has in the last three years received research grant support administered through Yale University School of Medicine from Targacept.
References
- 1.Leon Jd, Dadvand M, Canuso C, White A, Stanilla J, Simpson G. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry. 1995;152:453–5. doi: 10.1176/ajp.152.3.453. [DOI] [PubMed] [Google Scholar]
- 2.Leon Jd, Diaz F. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–57. doi: 10.1016/j.schres.2005.02.010. [DOI] [PubMed] [Google Scholar]
- 3.Olincy A, Young D, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry. 1997;42:1–5. doi: 10.1016/S0006-3223(96)00302-2. [DOI] [PubMed] [Google Scholar]
- 4.Capasso R, Lineberry T, Bostwick J, Decker P, Sauver JS. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res. 2008;98:287–94. doi: 10.1016/j.schres.2007.10.005. [DOI] [PubMed] [Google Scholar]
- 5.Adler L, Hoffer L, Wiser A, Freeman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993;150:1856–61. doi: 10.1176/ajp.150.12.1856. [DOI] [PubMed] [Google Scholar]
- 6.Adler L, Olincy A, Waldo M, Harris J, Griffith J, Stevens K, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bull. 1998;24:189–202. doi: 10.1093/oxfordjournals.schbul.a033320. [DOI] [PubMed] [Google Scholar]
- 7.Winterer G. Why do patients with schizophrenia smoke? Curr Opin Psychiatry. 2010;23:112–9. doi: 10.1097/YCO.0b013e3283366643. [DOI] [PubMed] [Google Scholar]
- 8.Sacco K, Bannon K, George T. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch General Psychiatry. 2005;62:649–59. doi: 10.1001/archpsyc.62.6.649. [DOI] [PubMed] [Google Scholar]
- 9.Ziedonis D, Hitsman B, Beckham J, Zvolensky M, Adler L, Audrain-McGovern J, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Respiration. 2008;10:1691–715. doi: 10.1080/14622200802443569. [DOI] [PubMed] [Google Scholar]
- 10.Breese C, Marks M, Logel J, Adams C, Sullivan B, Collins A, et al. Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Therap. 1997;282:7–13. [PubMed] [Google Scholar]
- 11.Cosgrove K, Ellis S, Al-Tikriti M, Jatlow P, Picciotto M, Baldwin R, et al., editors. Assessment of the effects of chronic nicotine on b2-nicotinic acetylcholine receptors in nonhuman primate using [I-123]5-IA-85830 and SPECT; Sixty-Sixth Annual Scientific Meeting of the College on Problems of Drug Dependence; San Juan, Puerto Rico. 2004. [Google Scholar]
- 12.Staley J, Krishnan-Sarin S, Cosgrove K, Krantzler E, Frohlich E, Perry E, et al. Human tobacco smokers in early abstinence have higher levels of beta2-nicotinic acetylcholine receptors than nonsmokers. Journal of Neuroscience. 2006;26(34):8707–14. doi: 10.1523/JNEUROSCI.0546-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Cosgrove K, Batis J, Bois F, Maciejewski P, I Esterlis IK, Stiklus S, et al. beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry. 2009;66:666–76. doi: 10.1001/archgenpsychiatry.2009.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Yates S, Bencherif M, Fluhler E, Lippiello P. Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or alpha 4 beta 2 receptors to nicotine. Biochem Pharmacol. 1995;50:2001–8. doi: 10.1016/0006-2952(95)02100-0. [DOI] [PubMed] [Google Scholar]
- 15.Breese C, Lee M, Adams C, Sullivan B, Logel J, Gillen K, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology. 2000;23:351–64. doi: 10.1016/S0893-133X(00)00121-4. [DOI] [PubMed] [Google Scholar]
- 16.D’Souza D, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, et al. Lower β2*-Nicotinic Acetylcholine Receptor Availability in Smokers with Schizophrenia. Am J Psychiatry. 2012;169:326–34. doi: 10.1176/appi.ajp.2011.11020189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Abreo M, Lin N-H, Garvey D, Gunn D, Hettinger A-M, Wasicak J, et al. Novel 3-Pyridyl Ethers with Subnanomolar Affinity for Central Neuronal Nicotinic Acetylcholine Receptors. J Med Chem. 1996;39:817–25. doi: 10.1021/jm9506884. [DOI] [PubMed] [Google Scholar]
- 18.Vaupel D, Mukhin A, Kimes A, Horti A, Koren A, London E. In vivo studies with [125I]5-IA 85380, a nicotinic acetylcholine receptor radioligand. NeuroReport. 1998;9:2311–7. doi: 10.1097/00001756-199807130-00030. [DOI] [PubMed] [Google Scholar]
- 19.Cosgrove K, Mitsis E, Frohlich FBE, Tamagnan G, Krantzler E, Perry E, et al. 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase. Journal of Nuclear Medicine. 2007;48:1633–40. doi: 10.2967/jnumed.107.042317. [DOI] [PubMed] [Google Scholar]
- 20.Esterlis I, Cosgrove K, Batis J, Bois F, Stiklus S, Perkins E, et al. Quantification of smoking induced occupancy of β2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. Journal of Nuclear Medicine. 2010;51:1226–33. doi: 10.2967/jnumed.109.072447. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Esterlis I, Cosgrove K, Petrakis I, McKee S, Bois F, Krantzler E, et al. SPECT imaging of nicotinic acetylcholine receptors in non-smoking heavy alcohol drinking individuals. Drug and Alcohol Dependence. 2010;108:146–50. doi: 10.1016/j.drugalcdep.2009.12.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Saricicek A, Esterlis I, Maloney K, Mineur Y, Ruf B, Muralidharan A, et al. Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder. American Journal of Psychiatry. 2012;169:851–9. doi: 10.1176/appi.ajp.2012.11101546. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Hannestad J, Cosgrove K, Dellagioia N, Perkins E, Bois F, Bhagwagar Z, et al. Changes in the Cholinergic System between Bipolar Depression and Euthymia as Measured with [123I]5IA Single Photon Emission Computed Tomography. Biol Psychiatry. 2013 doi: 10.1016/j.biopsych.2013.04.004. Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Mukhin A, Gundisch D, Horti A, Koren A, Tamagnan G, Kimes A, et al. 5-Iodo-A-85830, an a4b2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol. 2000;57:642–9. doi: 10.1124/mol.57.3.642. [DOI] [PubMed] [Google Scholar]
- 25.Trenerry M, Crosson B, DeBoe J, Leber W. Stroop Neuropsychological Screening Test. Psychological Assessment Resources. 1989 [Google Scholar]
- 26.Joy S, Kaplan E, Fein D. Speed and memory in the WAIS-III Digit Symbol - Coding subtest across the adult lifespan. Archives of Clinical Neuropsychology. 2004;19:759–67. doi: 10.1016/j.acn.2003.09.009. [DOI] [PubMed] [Google Scholar]
- 27.Esterlis I, Mitsis E, Batis J, Bois F, Picciotto M, Stiklus S, et al. Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. International Journal Neuropsychopharmacology. 2011;14:389–98. doi: 10.1017/S1461145710001227. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Staley J, Dyck Cv, Weinzimmer D, Brenner E, Baldwin R, Tamagnan G, et al. Iodine-123-5-IA-85380 SPECT Measurement of Nicotinic Acetylcholine Receptors in Human Brain by the Constant Infusion Paradigm:Feasibility and Reproducibility. J Nucl Med. 2005;46:1466–72. [PubMed] [Google Scholar]
- 29.Zoghbi S, Tamagnan G, Fujita M, Baldwin RM, Amici L, Tikriti MA, et al. Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. Nucl Med Biol. 2001;28:91–6. doi: 10.1016/S0969-8051(00)00188-8. [DOI] [PubMed] [Google Scholar]
- 30.Innis R, Cunningham V, Delforge J, Fujita M, Gjedde A, Gunn R, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow & Metabolism. 2007;27:1533–9. doi: 10.1038/sj.jcbfm.9600493. [DOI] [PubMed] [Google Scholar]
- 31.Wonnacott S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci. 1990;11(6):216–9. doi: 10.1016/0165-6147(90)90242-z. [DOI] [PubMed] [Google Scholar]
- 32.Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron. 1996;16(5):905–8. doi: 10.1016/s0896-6273(00)80112-9. [DOI] [PubMed] [Google Scholar]
- 33.Brody AL, Mandelkern MA, London ED, Olmstead RE, Farahi J, Scheibal D, et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Archives of general psychiatry. 2006;63(8):907–15. doi: 10.1001/archpsyc.63.8.907. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Luckhaus C, Henning U, Ferrea S, Musso F, Mobascher A, Winterer G. Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms. J Neural Transm. 2012;119(5):587–95. doi: 10.1007/s00702-011-0743-1. [DOI] [PubMed] [Google Scholar]
- 35.Ziedonis DM, Kosten TR, Glazer WM, Frances RJ. Nicotine dependence and schizophrenia. Hospital & community psychiatry. 1994;45(3):204–6. doi: 10.1176/ps.45.3.204. [DOI] [PubMed] [Google Scholar]
- 36.Herran A, de Santiago A, Sandoya M, Fernandez MJ, Diez-Manrique JF, Vazquez-Barquero JL. Determinants of smoking behaviour in outpatients with schizophrenia. Schizophr Res. 2000;41(2):373–81. doi: 10.1016/s0920-9964(99)00082-1. [DOI] [PubMed] [Google Scholar]
- 37.Patkar AA, Gopalakrishnan R, Lundy A, Leone FT, Certa KM, Weinstein SP. Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. J Nerv Ment Dis. 2002;190(9):604–10. doi: 10.1097/00005053-200209000-00005. [DOI] [PubMed] [Google Scholar]
- 38.Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992;149(9):1189–94. doi: 10.1176/ajp.149.9.1189. [DOI] [PubMed] [Google Scholar]
- 39.Hall RG, Duhamel M, McClanahan R, Miles G, Nason C, Rosen S, et al. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. J Nerv Ment Dis. 1995;183(7):468–71. doi: 10.1097/00005053-199507000-00008. [DOI] [PubMed] [Google Scholar]
- 40.Fukui K, Kobayashi T, Hayakawa S, Koga E, Okazaki S, Kawashima Y, et al. Smoking habits in chronic schizophrenics. Arukoru Kenkyuto Yakubutsu Ison. 1995;30(6):447–54. [PubMed] [Google Scholar]
- 41.Addington J, el-Guebaly N, Campbell W, Hodgins DC, Addington D. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry. 1998;155(7):974–6. doi: 10.1176/ajp.155.7.974. [DOI] [PubMed] [Google Scholar]
- 42.Dalack GW, Meador-Woodruff JH. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res. 1996;22(2):133–41. doi: 10.1016/s0920-9964(96)80441-5. [DOI] [PubMed] [Google Scholar]
- 43.Dalack GW, Meador-Woodruff JH. Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia. Nicotine Tob Res. 1999;1(1):53–7. doi: 10.1080/14622299050011151. [DOI] [PubMed] [Google Scholar]
- 44.Barnes M, Lawford BR, Burton SC, Heslop KR, Noble EP, Hausdorf K, et al. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust N Z J Psychiatry. 2006;40(6-7):575–80. doi: 10.1080/j.1440-1614.2006.01841.x. [DOI] [PubMed] [Google Scholar]
- 45.Kotov R, Guey LT, Bromet EJ, Schwartz JE. Smoking in schizophrenia: diagnostic specificity, symptom correlates, and illness severity. Schizophr Bull. 2010;36(1):173–81. doi: 10.1093/schbul/sbn066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Kao YC, Liu YP, Cheng TH, Chou MK. Cigarette smoking in outpatients with chronic schizophrenia in Taiwan: relationships to socio-demographic and clinical characteristics. Psychiatry Res. 2011;190(2-3):193–9. doi: 10.1016/j.psychres.2011.05.016. [DOI] [PubMed] [Google Scholar]
- 47.Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull. 1997;23(2):247–54. doi: 10.1093/schbul/23.2.247. [DOI] [PubMed] [Google Scholar]
- 48.Ucok A, Polat A, Bozkurt O, Meteris H. Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci. 2004;58(4):434–7. doi: 10.1111/j.1440-1819.2004.01279.x. [DOI] [PubMed] [Google Scholar]
- 49.Taiminen TJ, Salokangas RK, Saarijarvi S, Niemi H, Lehto H, Ahola V, et al. Smoking and cognitive deficits in schizophrenia: a pilot study. Addictive behaviors. 1998;23(2):263–6. doi: 10.1016/s0306-4603(97)00028-2. [DOI] [PubMed] [Google Scholar]
- 50.Liao DL, Yang JY, Lee SM, Chen H, Tsai SJ. Smoking in chronic schizophrenic inpatients in taiwan. Neuropsychobiology. 2002;45(4):172–5. doi: 10.1159/000063666. [DOI] [PubMed] [Google Scholar]
- 51.Tang YL, George TP, Mao PX, Cai ZJ, Chen Q. Cigarette smoking in Chinese male inpatients with schizophrenia: a cross-sectional analysis. J Psychiatr Res. 2007;41(1-2):43–8. doi: 10.1016/j.jpsychires.2005.10.009. [DOI] [PubMed] [Google Scholar]
- 52.Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology. 2002;27(3):479–97. doi: 10.1016/S0893-133X(02)00324-X. [DOI] [PubMed] [Google Scholar]
- 53.Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165(3):1040–7. doi: 10.1176/appi.ajp.2008.07071135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63(3):630–8. doi: 10.1001/archpsyc.63.6.630. [DOI] [PubMed] [Google Scholar]
- 55.Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy. Schizophr Res. 2013 doi: 10.1016/j.schres.2013.05.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013;38(3):968–75. doi: 10.1038/npp.2012.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Grenhoff J, Aston-Jones G, Svensson TH. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand. 1986;128(3):351–8. doi: 10.1111/j.1748-1716.1986.tb07988.x. [DOI] [PubMed] [Google Scholar]
- 58.Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. European journal of pharmacology. 2000;393(1-3):295–314. doi: 10.1016/s0014-2999(00)00122-9. [DOI] [PubMed] [Google Scholar]
- 59.Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR. Nicotine-induced dopamine release in primates measured with [C-11]raclopride PET. Neuropsychopharmacology. 2004;29(3):259–68. doi: 10.1038/sj.npp.1300287. [DOI] [PubMed] [Google Scholar]
- 60.Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. The American journal of psychiatry. 1991;148(3):1474–86. doi: 10.1176/ajp.148.11.1474. [DOI] [PubMed] [Google Scholar]
- 61.Caeyenberghs K, Leemans L, Leunissen I, Gooijers J, Michiels K, Sunaert S, et al. Altered structural networks and executive deficits in traumatic brain injury patients. Brain Struct Funct. 2012 doi: 10.1007/s00429-012-0494-2. Epub ahead of print. [DOI] [PubMed] [Google Scholar]
- 62.Sarter M, Nelson C, Bruno J. Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull. 2005;31:117–38. doi: 10.1093/schbul/sbi006. [DOI] [PubMed] [Google Scholar]
- 63.Furey M, Pietrini P, Alexander G, Schapiro M, Horwitz B. Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans. Brain Res Bull. 2000;51:213–8. doi: 10.1016/s0361-9230(99)00219-1. [DOI] [PubMed] [Google Scholar]
- 64.Sacco K, Bannon K, George T. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. Journal of Psychopharmacology. 2004;18:457–74. doi: 10.1177/0269881104047273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Velligan D, Brenner R, Sicuro F, Walling D, Riesenberg R, Sfera A, et al. Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophr Res. 2012;134(3):59–64. doi: 10.1016/j.schres.2011.10.004. [DOI] [PubMed] [Google Scholar]
- 66.Shim J, Jung D, Jung S, Seo Y, Cho D, Lee J, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology. 2012;37:660–8. doi: 10.1038/npp.2011.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Hong L, Thaker G, McMahon R, Summerfelt A, Rachbeisel J, Fuller R, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 2011;68:1195–206. doi: 10.1001/archgenpsychiatry.2011.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Terry AV, Jr., Gearhart DA, Mahadik SP, Warsi S, Waller JL. Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain. Neuroscience. 2006;140(3):1277–87. doi: 10.1016/j.neuroscience.2006.03.011. [DOI] [PubMed] [Google Scholar]
- 69.Cosgrove K, Esterlis I, McKee S, Bois F, Seibyl J, Krishnan-Sarin CMS, et al. Sex differences in availability of β2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers. Archives of General Psychiatry. 2012;69:418–27. doi: 10.1001/archgenpsychiatry.2011.1465. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.